teristics remain poorly understood. We report a case of chronic retinal detachment with large macular and peripheral retinal pseudocysts and discuss the histologic features of such retinal macro-pseudocysts and their implications.
Report of a Case | A man in his mid-20s with a remote history of blunt injury to his left eye presented with a 10-year history of chronic blurred vision in the left eye. Results of an examination of the left eye showed visual acuity of counting fingers, a normal anterior segment, and an inferior retinal detachment involving the macula ( Figure 1A) . A retinal tear 2 clock-hours in size was noted in the inferotemporal quadrant near the ora serrata. Two large retinal macro-pseudocysts, posterior to the retinal break, were confirmed by ultrasonography to be contiguous with the detached retina ( Figure 1B ). Optical coherence tomography through a separate foveal retinal macropseudocyst revealed a schisis-like cavity ( Figure 1C ). The patient underwent surgical repair with 23-gauge pars plana vitrectomy, scleral buckle placement, inferior retinectomy, endolaser, and injection of perfluoropropane. Intraoperatively, the peripheral retinal macro-pseudocysts ( Figure 1D ) and a small area of the adjacent detached retina were aspirated, then resected en bloc and sent for pathologic examination. At the patient's 6-month postoperative visit, the retina remained attached, and his visual acuity showed a slight improvement at Snellen 20/400 OS.
Discussion | To our knowledge, this is the first reported case with multimodal imaging of concurrent macular and peripheral retinal macro-pseudocysts associated with chronic retinal detachment. By comparing the peripheral retinal macropseudocyst with the adjacent detached retina, we conclude that the peripheral retinal macro-pseudocyst is a localized splitting of the detached retina, with an anterior portion consisting of atrophied inner retinal layers (Figure 2A Figure 2C and D) . The anterior portion of the pseudocyst contained blood vessels that stained positive with CD34 antibody and periodic acid-Schiff, and ganglion cells and cells of the inner nuclear layer that stained positive with NeuN, a neuronal nuclear antigen ( Figure 2B ). The posterior portion of the pseudocyst stained negative for the CD34 antigen and NeuN ( Figure 2D ). In addition, immunohistochemical staining for keratin was negative in our specimen, indicating the absence of epithelial cells. Few pathologic reports of retinal macropseudocysts exist, and our observation is consistent with pathologic specimens obtained by Zimmerman and Spencer 3 and Marcus and Aaberg, 4 who indicated that these pseudocysts were located in the outer plexiform layer, although their reports lacked immunohistochemical confirmation. In addition, optical coherence tomography through the macular macro-pseudocyst also revealed splitting of the retina in the patient, similar to that reported by Tripathy et al. 5 Our histologic findings, together with ultrasonographic and optical coherence tomographic findings, suggest that what is commonly referred to as a macrocyst in this clinical context is a misnomer.
ers (
The inner wall of a cyst, by definition, is lined by epithelium. Classic teaching dictates that drainage of a cyst without removal of the cyst wall en bloc will lead to the reaccumulation of fluid. In the clinical context of retinal macropseudocysts associated with chronic retinal detachment, it is important to understand the pathogenesis of these pseudocysts, which has surgical implications. Specifically, because these macro-pseudocysts are not real cysts, they need not be resected en bloc during surgical retinal reattachment, thus allowing for the preservation of wide areas of the retina.
Conclusions | Retinal macro-pseudocysts can be seen in the setting of chronic retinal detachments. Our histologic, optical coherence tomographic, and ultrasonographic findings suggest that these macro-pseudocysts are not real cysts but are formed by the splitting of the retinal layers instead. This observation is important for choosing the optimal surgical approach in this clinical setting. Additional Contributions: We thank the patient for granting permission to publish this information. Lead is a well-studied environmental toxin that accumulates in bone, retinal tissues, and other soft tissues. 2, 3 Lead exposure increases oxidative stress and inflammation, both of which have been associated with the development of AMD. 2 Postmortem studies indicate that the median lead levels are 50% higher in the neural retinas of those with AMD than those without AMD. 2 In a recent national, population-based study in Korea, higher blood lead levels were significantly associated with both early and late AMD, even after adjusting for many known AMD risk factors. 4 Other studies of nonoccupationally exposed participants have found that lead exposure is also associated with cataract formation in men and wide-angle glaucoma in women. 4 Before the phaseout of leaded gasoline in the 1970s and 1980s, exposure to lead was extremely high. Subsequent generations have much lower lifetime exposures. Tibia lead level, a marker of cumulative lifetime exposure, has an estimated halflife of decades. Tibia bone lead measures taken in the 1990s of people who were not occupationally exposed to lead suggest that the average lifetime exposure to lead for people born before 1925 (25 μg/g-28 μg/g) 5 was approximately 50% higher than those born between 1926 and 1935 (18-22 μg/g), 5 twice that of those born between 1936 and 1945 (13 μg/g), 5 and 5 times that of those born between 1965 and 1982 (4-5 μg/g). 3 This decline in exposure parallels the generational decline in the incidence of AMD. Lead in bone is slowly released to other tissues and is therefore an endogenous source of lead in addition to a marker of cumulative lifetime exposure to exogenous sources. 3 Future studies could use radiographic fluorescence 5 to determine if tibia bone lead levels in those with macular degeneration are significantly greater than those of age-matched control participants. If lead exposure is a major environmental risk factor for AMD, the incidence rate of AMD should continue to decline until those who were born after the phaseout of leaded gasoline reach old age (ie, around 2065).
Esme Fuller-Thomson, PhD In Reply Fuller-Thomson suggests the decline in the incidence of age-related macular degeneration (AMD) observed in our study might reflect the decline in lead exposure with its removal from gasoline and paint. We agree there is good evidence that blood lead levels have decreased in the United States since these regulations were introduced. Furthermore, lead exposure has been associated with the risk for cardiovascular disease, which also declined during the 20th century, although it is not known if decreasing lead exposure contributed to that trend. 1, 2 Lead exposure may explain the declining incidence of AMD only if it is associated with AMD. Limited supporting evidence comes from 2 cross-sectional association studies from the Korean National Health and Nutrition Examination Survey. 3, 4 Although blood lead levels were not measured in the Beaver Dam Eye Study, baseline levels were measured in the Beaver Dam Offspring Study cohort to test specific hypotheses about other age-related conditions. In response to this letter, my coauthors and I conducted exploratory analyses that showed elevated age-adjusted and sex-adjusted associations between upper-quintile lead levels (>2.06 μg/dL) and doubling of lead levels and the 5-year incidence of AMD (upper quintile: relative risk, 1.75; 95% CI, 0.59-5.21; and doubling of levels: relative risk, 1.60; 95% CI, 1.06-2.40). However, in both cases, the bounds of the 95% CI included or were close to 1.0, reducing confidence that the increased risks were real. Without data for the older generations who were seen primarily in the Beaver Dam Eye Study and appropriate controls for other
